Hong Kong

SciClone profit up 4.3% to RMB622.7m in H1 2021

Its revenue rose 14.7% to RMB1.3b in the same period. 

SciClone profit up 4.3% to RMB622.7m in H1 2021

Its revenue rose 14.7% to RMB1.3b in the same period. 

HKMC opens integrated medical centre in Central

The facility will offer 11 medicine specialties. 

Scivita Medical bags CNÂ¥400m in Series B funding round

Scivita Medical is a Hong Kong-based maker of endoscopy products.

Hong Kong Baptist Hospital earned two trophies at the Healthcare Asia Awards

Its accelerated response to COVID -19 was recognised as it supported both their patients and frontline staff.

Strong state commitment boosts Hong Kong's healthcare sector

The government has allocated 15% of its 2021 budget to healthcare.

Hutchinson Telecomm, Bowtie Life roll out telemedicine service

First time users will get a waiver on consultation fees, two days’ basic medication, and free delivery.

HKEX greenlights Hangzhou Tigermed's IPO

The listing looks to raise about $1b.

Check out HKU's remote COVID-19 disease surveillance programme

The data collected through the program could be used to identify patterns for facilitating early detection of the disease.

Family office Black Spade Capital invests in My Platform

This is Lawrence Ho’s first move in the medical IT space.

Nine in 10 consumers unaware what counterfeit medicines are: survey

More than half of respondents believe that it is the same as generic medicine.

Hong Kong earmarks $258,000 per R&D project to curb COVID-19

It will fund R&D trials related to detection, diagnosis or surveillance of the virus.

Teledentistry company SmileDirectClub expands to Hong Kong

The company specialises in remote teeth straightening therapy.

Hong Kong Hospital Authority launches centralised HA Go app

Its new features include a specialist outpatient clinic booking service.

Investment firm Wellington Management closes $393m biomedical fund

The fund will allot investments into private biotech companies.

Biopharma firm SinoMab BioScience seeks $1.75b in IPO

It is focused on the treatment of immunological diseases, with a focus on mAb-based biologics.